570 related articles for article (PubMed ID: 16898258)
1. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
[TBL] [Abstract][Full Text] [Related]
2. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
3. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
[TBL] [Abstract][Full Text] [Related]
4. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
Verloes A; Massin M; Lombet J; Grattagliano B; Soyeur D; Rigo J; Koulischer L; Van Hoof F
Am J Med Genet; 1997 Oct; 72(2):135-42. PubMed ID: 9382133
[TBL] [Abstract][Full Text] [Related]
5. [A retrospective study of six patients with late-onset Pompe disease].
Saux A; Laforet P; Pagès AM; Figarella-Branger D; Pellissier JF; Pagès M; Labauge P
Rev Neurol (Paris); 2008 Apr; 164(4):336-42. PubMed ID: 18439925
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
Klinge L; Straub V; Neudorf U; Voit T
Neuropediatrics; 2005 Feb; 36(1):6-11. PubMed ID: 15776317
[TBL] [Abstract][Full Text] [Related]
7. Long-term enzyme replacement therapy for pompe disease with recombinant human alpha-glucosidase derived from chinese hamster ovary cells.
Rossi M; Parenti G; Della Casa R; Romano A; Mansi G; Agovino T; Rosapepe F; Vosa C; Del Giudice E; Andria G
J Child Neurol; 2007 May; 22(5):565-73. PubMed ID: 17690063
[TBL] [Abstract][Full Text] [Related]
8. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
Katzin LW; Amato AA
J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
[TBL] [Abstract][Full Text] [Related]
9. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail.
Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT
J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978
[TBL] [Abstract][Full Text] [Related]
10. Pompe disease: current state of treatment modalities and animal models.
Geel TM; McLaughlin PM; de Leij LF; Ruiters MH; Niezen-Koning KE
Mol Genet Metab; 2007 Dec; 92(4):299-307. PubMed ID: 17826266
[TBL] [Abstract][Full Text] [Related]
11. [Pompe's disease. Part II. Treatment strategies and enzyme replacement].
Illés Z; Várdi Visy K
Ideggyogy Sz; 2009 Sep; 62(9-10):299-307. PubMed ID: 19835271
[TBL] [Abstract][Full Text] [Related]
12. Anaesthetic management of infants with glycogen storage disease type II: a physiological approach.
Ing RJ; Cook DR; Bengur RA; Williams EA; Eck J; Dear Gde L; Ross AK; Kern FH; Kishnani PS
Paediatr Anaesth; 2004 Jun; 14(6):514-9. PubMed ID: 15153218
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy in severe adult-onset glycogen storage disease type II.
Ravaglia S; Danesino C; Pichiecchio A; Repetto A; Poloni GU; Rossi M; Fratino P; Moglia A; Costa A
Adv Ther; 2008 Aug; 25(8):820-9. PubMed ID: 18704279
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T
Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT
Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
[TBL] [Abstract][Full Text] [Related]
16. Gingival overgrowth in Pompe disease: a case report.
de Gijt JP; van Capelle CI; Oosterhuis JW; van der Ploeg AT; van der Wal KG
J Oral Maxillofac Surg; 2011 Aug; 69(8):2186-90. PubMed ID: 21783002
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
[TBL] [Abstract][Full Text] [Related]
18. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
[TBL] [Abstract][Full Text] [Related]
19. Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line.
Martiniuk F; Chen A; Donnabella V; Arvanitopoulos E; Slonim AE; Raben N; Plotz P; Rom WN
Biochem Biophys Res Commun; 2000 Oct; 276(3):917-23. PubMed ID: 11027569
[TBL] [Abstract][Full Text] [Related]
20. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy.
Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P
Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]